

Aspirin in patients admitted to hospital with COVID-19 controlled, open-label, platform trial

Lancet, The

399, 143-151

DOI: [10.1016/s0140-6736\(21\)01825-0](https://doi.org/10.1016/s0140-6736(21)01825-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19. <i>Metabolites</i> , 2021, 11, 826.	2.9	6
2	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. <i>Lancet Respiratory Medicine</i> , 2022, 10, 214-220.	10.7	37
3	Ann Robinson's research reviews 3 December 2021. <i>BMJ</i> , 2021, 375, n3006.	6.0	0
4	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	7.4	89
5	Can low-dose aspirin help the RECOVERY of patients hospitalized with COVID-19?. <i>European Heart Journal</i> , 2022, 43, 714-715.	2.2	0
6	Sickle cell disease and COVID-19 in pregnant women. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102328.	1.3	0
7	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 802566.	2.4	7
8	Aspirin and Infection: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 263.	3.2	9
9	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	2.2	297
10	Another piece in the COVID-19 treatment puzzle. <i>Lancet</i> , 2022, 399, 609-610.	13.7	6
11	Adverse Outcome in COVID-19 Is Associated With an Aggravating Hypo-Responsive Platelet Phenotype. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 795624.	2.4	23
12	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	14.4	175
14	Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial. <i>Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlap 10 Tf 50 257 Td (</i>		
15	Health crisis: What opportunities for clinical drug research?. <i>Therapie</i> , 2022, 77, 59-67.	1.0	2
16	Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial. <i>Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlap 10 Tf 50 177 Td (</i>		
17	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. <i>Nature Communications</i> , 2022, 13, 946.	12.8	30
18	Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Frontiers in Immunology</i> , 2022, 13, 837629.	4.8	14
19	Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. <i>Nature</i> , 2022, 605, 146-151.	27.8	82

#	ARTICLE	IF	CITATIONS
20	Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	2.4	7
21	Platelets in Viral Infections – “ Brave Soldiers or Trojan Horses. <i>Frontiers in Immunology</i> , 2022, 13, 856713.	4.8	14
22	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3338.	4.1	11
23	Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19. <i>JAMA Network Open</i> , 2022, 5, e223890.	5.9	31
24	Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation. <i>Frontiers in Immunology</i> , 2022, 13, 844701.	4.8	15
26	Role of Acute Thrombosis in COVID-19. <i>Critical Care Clinics</i> , 2022, , .	2.6	3
27	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	3.5	15
28	Shining a light on platelet activation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	3.8	3
29	Platelet activation state in early stages of Covid-19. <i>Minerva Anestesiologica</i> , 2022, , .	1.0	2
30	Thromboinflammation and Antithrombotics in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1234.	7.4	9
31	Effect of Antiplatelet Therapy on Survival and Organ Support – Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	7.4	83
32	Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?. <i>Thrombosis Research</i> , 2022, 213, 179-194.	1.7	17
33	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	1.6	13
34	Prothrombotic Phenotype in COVID-19: Focus on Platelets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13638.	4.1	21
35	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. <i>CMAJ Open</i> , 2022, 10, E379-E389.	2.4	3
36	New Antivirals and Immune Therapies for COVID-19 Infection. <i>Archivos De Bronconeumologia</i> , 2022, , .	0.8	0
37	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 062-072.	2.7	13
39	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2695.	2.4	4

#	ARTICLE	IF	CITATIONS
40	Association between Severe SARS-CoV-2 Infection and Severe Acute Pancreatitis in Pregnancy and Postpartum. <i>Journal of Clinical Medicine</i> , 2022, 11, 2554.	2.4	2
41	Risk of arterial and venous thromboses after COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, , .	9.1	6
42	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	2.1	29
43	Critical Influenza and COVID-19â€™A Comparative Nationwide Case-Control Study. , 2022, 4, e0705.		2
44	Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19. <i>American Journal of Cardiology</i> , 2022, 175, 185-187.	1.6	1
45	Editorial: Platelet Function in COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	1
46	Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. <i>Clinical Microbiology and Infection</i> , 2022, , .	6.0	0
47	Acute Coronary Syndrome in the COVID-19 Eraâ€™Differences and Dilemmas Compared to the Pre-COVID-19 Era. <i>Journal of Clinical Medicine</i> , 2022, 11, 3024.	2.4	11
48	To escalate thromboprophylactic heparin intensity in COVIDâ€™19 or not? That is still the question. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12738.	2.3	2
49	Antithrombotic agents in patients with COVID-19. <i>Cmaj</i> , 2022, 194, E704-E704.	2.0	1
50	No association of lowâ€™dose aspirin with severe COVIDâ€™19 in France: A cohort of 31.1 million people without cardiovascular disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12743.	2.3	4
51	Time to re-think how we evaluate platelet function. <i>Minerva Anestesiologica</i> , 2022, 88, .	1.0	0
52	Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1403-1420.	1.9	10
53	D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6880.	4.1	1
54	COVID 19; Lipid Disruption is Pushing the Envelope.. <i>Journal of Lipid Research</i> , 2022, , 100240.	4.2	0
55	A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection. <i>Inflammopharmacology</i> , 2022, 30, 1475-1476.	3.9	2
56	COVIDâ€™19 coagulopathy â€™ what should we treat?. <i>Experimental Physiology</i> , 2022, 107, 749-758.	2.0	8
57	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature. <i>Cardiovascular Research</i> , 2022, 118, 3085-3096.	3.8	17

#	ARTICLE	IF	CITATIONS
58	Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-19 Registry. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
59	Platelet Activation and Thrombosis in COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 055-061.	2.7	17
60	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
61	Thromboinflammation: From Atherosclerosis to COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 1103-1112.	2.4	31
62	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	3.8	23
63	New chemiluminescent method of acetylsalicylic acid determination based on terbium(III)-sensitized Fenton system. <i>Journal of Luminescence</i> , 2022, 250, 119124.	3.1	3
64	Post-COVID-19 non-traumatic iliopsoas hematoma: A case report. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 61-64.	0.9	1
65	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	3.7	46
66	Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	9
67	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. <i>Neurotherapeutics</i> , 2022, 19, 1435-1466.	4.4	22
68	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. <i>Lancet, The</i> , 2022, 400, 359-368.	13.7	146
70	Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377.	1.7	3
71	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. <i>Thrombosis Journal</i> , 2022, 20, .	2.1	3
72	The role of platelets, neutrophils and endothelium in COVID-19 infection. <i>Expert Review of Hematology</i> , 2022, 15, 727-745.	2.2	7
73	Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. <i>Lancet Infectious Diseases, The</i> , 2023, 23, e22-e33.	9.1	38
74	Cardiac megakaryocytes in SARS-CoV-2 positive autopsies. <i>Histopathology</i> , 0, , .	2.9	0
75	Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis. <i>American Heart Journal Plus</i> , 2022, 20, 100191.	0.6	0
77	Antithrombotiques chez les patients atteints de COVID-19. <i>Cmaj</i> , 2022, 194, E1074-E1075.	2.0	0

#	ARTICLE	IF	CITATIONS
78	Peculiarities of hemostasis in patients with COVID-19. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 876-883.	0.8	0
79	Understanding COVID-19-associated coagulopathy. <i>Nature Reviews Immunology</i> , 2022, 22, 639-649.	22.7	137
80	Novel Strategies for the Treatment of COVID-19. <i>Drugs in R and D</i> , 2022, 22, 257-262.	2.2	5
81	SARS-CoV-2 and COVID-19: A Narrative Review. , 0, 79, .		9
82	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10372.	4.1	3
83	Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. <i>Thrombosis Research</i> , 2022, 219, 95-101.	1.7	5
84	Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. <i>Circulation</i> , 2022, 146, 1344-1356.	1.6	39
85	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 430-436.	0.6	0
86	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 983-984.	0.9	2
87	Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS). <i>Archivos De Bronconeumologia</i> , 2022, 58, 746-753.	0.8	7
88	Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as therapeutic target in COVID-19. <i>Blood Advances</i> , 0, , .	5.2	8
89	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	4.1	4
90	The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
91	COVID-19 Thrombotic Complications and Therapeutic Strategies. <i>Annual Review of Medicine</i> , 2023, 74, 15-30.	12.2	4
92	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	10
93	Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	1.7	8
94	Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
95	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. <i>Biomedicines</i> , 2022, 10, 2620.	3.2	6

#	ARTICLE	IF	CITATIONS
96	Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID- 19. Egyptian Journal of Anaesthesia, 2022, 38, 629-635.	0.5	0
97	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 1169-1177.	10.7	14
98	Aspirin Therapy in COVID-19: Prevention of NETosis. Archivos De Bronconeumologia, 2023, 59, 129.	0.8	1
99	Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism. Journal of Clinical Medicine, 2022, 11, 6011.	2.4	2
100	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2023, 49, 816-832.	2.7	12
101	Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19. Trials, 2022, 23, .	1.6	0
102	All-cause and in-hospital mortality after aspirin use in patients hospitalized with COVID-19: a systematic review and meta-analysis. Biology Methods and Protocols, 2022, 7, .	2.2	1
103	Response to Aspirin Therapy in COVID-19: Prevention of NETosis. Archivos De Bronconeumologia, 2023, 59, 130.	0.8	2
104	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Frontiers in Pharmacology, 0, 13, .	3.5	8
105	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	9.6	67
106	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. Journal of Clinical Medicine, 2022, 11, 5997.	2.4	13
107	Surging ICU during COVID-19 pandemic: an overview. Current Opinion in Critical Care, 2022, 28, 638-644.	3.2	11
108	Not to be sneezed at: cardiovascular disease after COVID-19 infection. Heart, 0, , heartjnl-2022-321748.	2.9	4
109	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update, 2022, , 100126.	0.9	0
110	The use of acetylsalicylic acid for prevention of cardiovascular complications in patients undergoing COVID-19. A review of current recommendations. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 656.	0.3	0
111	Aspirin and P2Y12 inhibitors in treating COVID-19. European Journal of Internal Medicine, 2023, 110, 101-103.	2.2	4
112	When to opt for preemptive anticoagulation with SARS-CoV-2 infection in the long-term care facilities. Aging Clinical and Experimental Research, 2022, 34, 3171-3177.	2.9	0
113	Is Rivaroxaban Superior to Enoxaparin for Thromboprophylaxis in Hospitalized Patients of COVID-19?. Journal of the Association of Physicians of India, The, 2022, 70, 97A-98.	0.0	0

#	ARTICLE	IF	CITATIONS
114	Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study. PLoS ONE, 2022, 17, e0277653.	2.5	0
116	Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021). American Journal of Health-System Pharmacy, 0, , .	1.0	0
117	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer, 2023, 181, 102-118.	2.8	2
119	Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19. European Journal of Medical Research, 2022, 27, .	2.2	5
120	Platelets in COVID-19 disease: friend, foe, or both?. Pharmacological Reports, 2022, 74, 1182-1197.	3.3	2
121	Thrombosis questions from the inpatient wards. Hematology American Society of Hematology Education Program, 2022, 2022, 481-490.	2.5	1
122	Anticoagulation Strategies in Non-â€œCritically Ill Patients with Covid-19. , 2023, 2, .		5
123	Antiplatelet Drugs in COVID-19: Mechanism of Action and Effect on Prognosis. Contemporary Cardiology, 2022, , 331-349.	0.1	0
124	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome â€œ Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
125	The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. Medicina (Lithuania), 2023, 59, 84.	2.0	1
126	The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic. Journal of Antimicrobial Chemotherapy, 2023, 78, 323-327.	3.0	4
127	Antithrombotic therapy in COVID-19 patients. Obstetrics, Gynecology and Reproduction, 2023, 16, 718-731.	0.5	1
128	Microvascular Thrombosis as a Critical Factor in Severe COVID-19. International Journal of Molecular Sciences, 2023, 24, 2492.	4.1	10
129	Prevalence of venous thromboembolism in patients undergoing diagnostic venous ultrasound during the first SARS-CoV-2 pandemic. Vasa - European Journal of Vascular Medicine, 0, , .	1.4	0
130	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	5.9	0
131	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS ONE, 2023, 18, e0274243.	2.5	0
132	Coronavirus disease 2019 infection and cerebrovascular diseases: an update on the pathophysiology and management. Current Opinion in Neurology, 2023, 36, 155-164.	3.6	1
133	Glycoprotein VI interplay with fibrin(ogen) in thrombosis. Journal of Thrombosis and Haemostasis, 2023, 21, 1703-1713.	3.8	6

#	ARTICLE	IF	CITATIONS
134	Thromboembolic Events in COVID-19. <i>Contemporary Cardiology</i> , 2022, , 201-216.	0.1	0
135	IL1RA mediated the effects of aspirin on COVID-19 severity: A Mendelian randomization study. <i>Journal of Infection</i> , 2023, 86, 410-411.	3.3	1
136	Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
137	Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation. <i>Archives of Cardiovascular Diseases</i> , 2023, 116, 183-191.	1.6	4
138	Antithrombotic therapy in patients with COVID-19: indications, pharmacotherapy and controversy. <i>Stroke and Vascular Neurology</i> , 2023, 8, 263-265.	3.3	1
139	COVID-19 and metabolic syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101753.	4.7	6
140	Comment on "The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic". Aspirin therapy in COVID-19: too soon to dismiss its benefits?. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1134-1135.	3.0	0
142	COVID-19 as a polymorphic inflammatory spectrum of diseases: a review with focus on the brain. <i>Acta Neuropsychiatrica</i> , 0, , 1-22.	2.1	1
143	COVID-19 and the Response to Antiplatelet Therapy. <i>Journal of Clinical Medicine</i> , 2023, 12, 2038.	2.4	5
144	COVID-19 and Pulmonary Angiogenesis: The Possible Role of Hypoxia and Hyperinflammation in the Overexpression of Proteins Involved in Alveolar Vascular Dysfunction. <i>Viruses</i> , 2023, 15, 706.	3.3	5
145	Effects of the circulating environment of COVID-19 on platelet and neutrophil behavior. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
147	Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. <i>European Respiratory Journal</i> , 2023, 61, 2202009.	6.7	0
148	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. <i>Canadian Journal of Cardiology</i> , 2023, 39, 865-874.	1.7	2
149	Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study. <i>Circulation</i> , 2023, 147, 1582-1593.	1.6	9
150	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 688-691.	0.9	0
151	NSAIDs, CGRP Monoclonal Antibodies, and COVID-19. <i>Headache</i> , 2023, , 191-201.	0.4	0
152	Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review. <i>Biomedicines</i> , 2023, 11, 1206.	3.2	5
154	Risk Factors for Postdischarge Major Thromboembolism and Mortality in Hospitalized Patients with COVID-19 with Cardiovascular Comorbidities: Insights from the CORE-19 Registry. <i>Thrombosis and Haemostasis</i> , 2023, 123, 1089-1099.	3.4	4

#	ARTICLE	IF	CITATIONS
155	Alterations in the megakaryocyte transcriptome impacts platelet function in sepsis and COVID-19 infection. <i>Thrombosis Research</i> , 2023, , .	1.7	0
156	A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2213-2222.	3.8	1
157	Clinical characteristics of COVID-19 associated vasculopathic diseases. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
158	Effect of P2Y12 Inhibitors on Organ Supportâ€Free Survival in Critically Ill Patients Hospitalized for COVID-19. <i>JAMA Network Open</i> , 2023, 6, e2314428.	5.9	4
159	Molecular mechanisms underlying the high mortality of hypervirulent <i>Klebsiella pneumoniae</i> and its effective therapy development. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	3
160	Tumour Necrosis Factor-Î±, Chemokines, and Leukocyte Infiltrate Are Biomarkers for Pathology in the Brains of Venezuelan Equine Encephalitis (VEEV)-Infected Mice. <i>Viruses</i> , 2023, 15, 1307.	3.3	0
161	Thromboprophylaxis for COVID-19: Time to ask for an extension?. <i>Vascular Medicine</i> , 2023, 28, 340-341.	1.5	1
163	Managing Labour in Women with COVID-19. <i>Journal of Clinical Medicine</i> , 2023, 12, 3980.	2.4	0
164	A Post-Pandemic Enigma: The Cardiovascular Impact of Post-Acute Sequelae of SARS-CoV-2. <i>Circulation Research</i> , 2023, 132, 1358-1373.	4.5	3
165	Antithrombotic therapy in the management of hospitalised patients with COVID-19. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2023, 84, 1-11.	0.5	0
166	Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. <i>European Heart Journal</i> , 0, , .	2.2	1
167	Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
168	A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11132.	4.1	1
169	Pharmacological and Non-pharmacological Intervention in Epidemic Prevention and Control: A Medical Perspective. <i>Lecture Notes on Data Engineering and Communications Technologies</i> , 2023, , 573-582.	0.7	0
170	Antiplatelet agents for the treatment of adults with COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	2
172	P-Selectin de-ACTIVation in COVID-19: What Have We Learned?. <i>Circulation</i> , 2023, 148, 391-393.	1.6	0
173	Thromboinflammation in acute injury: infections, heatstroke, and trauma. <i>Journal of Thrombosis and Haemostasis</i> , 2024, 22, 7-22.	3.8	8
174	Impairment of platelet function in both mild and severe <sc>COVID</sc>â€19 patients. <i>British Journal of Haematology</i> , 2023, 203, 656-667.	2.5	0

#	ARTICLE	IF	CITATIONS
175	Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMIâ€‘COVIDâ€‘19 Registry. Internal and Emergency Medicine, 0, , .	2.0	1
176	Outcomes and characteristics of patients hospitalized for COVID-19 in British Columbia, Ontario and Quebec during the Omicron wave. CMAJ Open, 2023, 11, E672-E683.	2.4	2
177	Ibuprofen, other NSAIDs and COVID-19: a narrative review. Inflammopharmacology, 2023, 31, 2147-2159.	3.9	2
178	The role of SARS-CoV-2-mediated NF-Î²B activation in COVID-19 patients. Hypertension Research, 2024, 47, 375-384.	2.7	2
179	COVID-19 thromboprophylaxis. New evidence. Revista EspaÃ±ola De AnestesiologÃ­a Y ReanimaciÃ³n (English Edition), 2024, 71, 34-47.	0.1	0
181	Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes and Endocrinology,the, 2023, 11, 905-914.	11.4	2
182	From Emergence to Endemicity: A Comprehensive Review of COVID-19. Cureus, 2023, , .	0.5	1
183	Deep phenotyping of the lipidomic response in COVIDâ€‘19 and nonâ€‘COVIDâ€‘19 sepsis. Clinical and Translational Medicine, 2023, 13, .	4.0	2
184	The influence of propolis plus <i>Hyoscyamus niger</i> L. against COVIDâ€‘19: A phase <i>II</i> , multicenter, placeboâ€‘controlled, randomized trial. Phytotherapy Research, 2024, 38, 400-410.	5.8	0
185	Longitudinal analysis of chest Q-SPECT/CT in patients with severe COVID-19. Respiratory Medicine, 2023, 220, 107461.	2.9	0
187	Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection. Expert Review of Hematology, 2023, 16, 1035-1048.	2.2	3
188	To Gain Insights into the Pathophysiological Mechanisms of the Thrombo-Inflammatory Process in the Atherosclerotic Plaque. International Journal of Molecular Sciences, 2024, 25, 47.	4.1	0
189	The Comparison of Soluble P-selectin, Anti-platelet Factor 4, and Platelet Maximum Aggregation Levels among Coronavirus Disease 2019 Patients. Journal of Applied Hematology, 2023, 14, 274-280.	0.3	0
190	Efficacy and limitations of repurposed drugs and vaccines for COVID-19. , 2024, 2, 100041.		1
191	Clinical trials of pharmacological interventions for SARSâ€‘CoVâ€‘2 published in leading medical journals report adherence but not how it was assessed.. British Journal of Clinical Pharmacology, 0, , .	2.4	0
192	The Effects of Anti-platelets and Micronutrients in the Recovery of COVID-19 Patients: A Review. Cureus, 2023, , .	0.5	0
193	Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child and Adolescent Health, 2024, 8, 190-200.	5.6	0
194	Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis. PLoS ONE, 2024, 19, e0297628.	2.5	0

#	ARTICLE	IF	CITATIONS
195	Dysregulated platelet function in patients with postacute sequelae of COVID-19. <i>Vascular Medicine</i> , 2024, 29, 125-134.	1.5	0
196	Investigational pharmacological agents for the treatment of ARDS. <i>Expert Opinion on Investigational Drugs</i> , 2024, 33, 243-277.	4.1	0
197	Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during "The Fifth Pandemic Wave" in Japan. <i>Kurume Medical Journal</i> , 2024, , .	0.1	0
198	Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study. <i>Nature Communications</i> , 2024, 15, .	12.8	0
199	2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2024, , .	3.8	0